Amgen Inc. $AMGN Shares Sold by Keybank National Association OH

Keybank National Association OH lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 181,556 shares of the medical research company’s stock after selling 2,027 shares during the quarter. Keybank National Association OH’s holdings in Amgen were worth $51,235,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sequoia Financial Advisors LLC grew its holdings in shares of Amgen by 2.3% during the third quarter. Sequoia Financial Advisors LLC now owns 160,646 shares of the medical research company’s stock worth $45,334,000 after buying an additional 3,619 shares in the last quarter. OLD National Bancorp IN boosted its position in Amgen by 296.2% during the second quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company’s stock worth $5,027,000 after acquiring an additional 13,460 shares during the last quarter. Atlantic Union Bankshares Corp boosted its position in Amgen by 165.0% during the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock worth $2,972,000 after acquiring an additional 6,627 shares during the last quarter. Davis Capital Management purchased a new stake in Amgen during the 3rd quarter valued at about $1,841,000. Finally, D.A. Davidson & CO. raised its holdings in Amgen by 2.6% in the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock valued at $68,590,000 after acquiring an additional 6,222 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of AMGN opened at $341.88 on Friday. The company has a market cap of $184.10 billion, a P/E ratio of 26.42, a PEG ratio of 3.02 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $353.25. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The firm’s 50 day moving average price is $332.60 and its 200 day moving average price is $309.22.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter in the previous year, the firm posted $5.58 earnings per share. The company’s quarterly revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is 73.57%.

Analyst Ratings Changes

Several brokerages have recently weighed in on AMGN. Piper Sandler boosted their target price on Amgen from $342.00 to $381.00 and gave the stock an “overweight” rating in a report on Friday, November 14th. Daiwa Capital Markets boosted their price objective on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. HSBC restated a “buy” rating and issued a $425.00 target price on shares of Amgen in a report on Wednesday, December 10th. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research report on Tuesday, January 20th. Finally, BMO Capital Markets upped their price objective on shares of Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average price target of $342.45.

Insider Activity

In other news, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.